Back

Effects of dapagliflozin in heart failure with preserved ejection fraction and chronic obstructive pulmonary disease: an analysis of the DELIVER trial

27 August 2023 (08:48 - 09:06)
Organised by: Logo
Congress Presentation Part of: State-of-the art treatment of HFmrEF and HFpEF in 2023 Treatment ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Jawad Haider Butt

Rigshospitalet - Copenhagen University Hospital, Copenhagen (Denmark)

3 More presentations in this session

Presentation thumbnail
State-of-the-art lecture on treatment of HFmrEF and HFpEF in 2023: insights from RCTs
Professor L. Kober (Copenhagen, DK)
Slides Video
Presentation thumbnail
Effect of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction treated with beta-blockers: the DELIVER trial
Doctor A. Peikert (Graz, AT)
Abstract Slides Video
Presentation thumbnail
Effect of dapagliflozin in patients in Asia with heart failure with mildly reduced or preserved ejection fraction: insights from DELIVER
Doctor X. Wang (Boston, US)
Abstract Slides Video

Access the full session

Session thumbnail
State-of-the art treatment of HFmrEF and HFpEF in 2023
Video

The Event

Event poster

ESC Congress 2023

27 August 2023 08:48 CET
You may be interested in
thumbnail
Congress Presentation
Audience Q&A
thumbnail
Congress Session
Meet the Experts: summation of the science - treatment of chronic heart failure in 2023
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources